Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy
Jonathan W. Friedberg(University of Rochester), Christopher A. Yasenchak(Willamette Valley Cancer Institute and Research Center), Vivian Jean M. Cline(Texas Oncology), Jerome H. Goldschmidt, Alev Akyol(Bristol-Myers Squibb (United States)), Rodolfo Bordoni(Georgia Cancer Specialists), Jingmin Liu(Southern Medical University), Dipti Patel‐Donnelly(Orthopaedic Research of Virginia), Timothy Larson(The US Oncology Network), Ralph V. Boccia(Center for Cancer and Blood Disorders), Adrija Mamidipalli(Seagen (United States))
Cited by 42
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
|New England Journal of Medicine|2010|425